Bibliographic details
Sanchez-de la Rosa R, Sabater E, Casado MA, Arroyo R. Cost-effectiveness analysis of disease modifiying drugs (interferons and glatiramer acetate) as first line treatments in remitting-relapsing multiple sclerosis patients. Journal of Medical Economics 2012; 15(3): 424-433
MeSH
Adjuvants, Immunologic /economics /therapeutic use; Antineoplastic Agents /economics /therapeutic use; Cost-Benefit Analysis; Glatiramer Acetate; Health Care Costs /statistics & Humans; Interferons /economics /therapeutic use; Multiple Sclerosis, Relapsing-Remitting /drug therapy; Peptides /economics /therapeutic use; Quality-Adjusted Life Years; Spain; numerical data